Profile of patients with rheumatic diseases undergoing treatment with anti-TNF agents in the Brazilian Public Health System (SUS), Belo Horizonte - MG
The aim of this study was to describe the baseline demographic and clinical characteristics as well as the functional status of a prospective cohort of patients with rheumatic diseases assisted by the Brazilian Public Health System (SUS). Data for 302 patients receiving tumor necrosis factor α inhibitors (anti-TNF agents) was collected through a standard form. Among patients, 229 (75.8%) were female and 155 (51.3%) were Caucasian; the mean age was 50.3 ± 12.8 years, and the mean disease duration was 9.9 ± 8.7 years. Among them 214 patients (70.9%) received adalimumab, 72 (23.8%) etanercept, and 16 (5.3%) infliximab. Mean Health Assessment Questionnaire-Disability Index (HAQ-DI) was 1.37 ± 0.67 for all participants. Poor functional response was associated with female gender, married patients and with a score of < 0.6 on the EuroQoL-5 dimensions (EQ-5D). Significant correlation was found between the HAQ-DI values, disease activity and quality of life (QOL). The results obtained in this study contribute to a better understanding of the clinical and demographic characteristics of patients with rheumatic diseases at the beginning of anti-TNF-agent treatment by SUS. Furthermore, our findings are consistent with another Brazilian and foreign cross-sectional investigations. This knowledge can be of great importance for further studies evaluating the effectiveness of biological agents, as well as, to contribute to improve the well-being of the patients with rheumatic diseases.
Main Authors: | , , , , , , , |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Universidade de São Paulo, Faculdade de Ciências Farmacêuticas
2015
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502015000300709 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:scielo:S1984-82502015000300709 |
---|---|
record_format |
ojs |
spelling |
oai:scielo:S1984-825020150003007092015-11-23Profile of patients with rheumatic diseases undergoing treatment with anti-TNF agents in the Brazilian Public Health System (SUS), Belo Horizonte - MGOliveira Junior,Haliton Alves deAlmeida,Alessandra MacielAcurcio,Francisco AssisSantos,Jéssica Barreto dosKakehasi,Adriana MariaAlvares,JulianaDabés,Clarice Gomes e SouzaCherchiglia,Mariangela Leal Rheumatic diseases/treatment/patients profile Rheumatoid arthritis Ankylosing spondylitis Psoriatic arthritis Brazilian public health system Anti-TNF agents/treatment of rheumatic diseases The aim of this study was to describe the baseline demographic and clinical characteristics as well as the functional status of a prospective cohort of patients with rheumatic diseases assisted by the Brazilian Public Health System (SUS). Data for 302 patients receiving tumor necrosis factor α inhibitors (anti-TNF agents) was collected through a standard form. Among patients, 229 (75.8%) were female and 155 (51.3%) were Caucasian; the mean age was 50.3 ± 12.8 years, and the mean disease duration was 9.9 ± 8.7 years. Among them 214 patients (70.9%) received adalimumab, 72 (23.8%) etanercept, and 16 (5.3%) infliximab. Mean Health Assessment Questionnaire-Disability Index (HAQ-DI) was 1.37 ± 0.67 for all participants. Poor functional response was associated with female gender, married patients and with a score of < 0.6 on the EuroQoL-5 dimensions (EQ-5D). Significant correlation was found between the HAQ-DI values, disease activity and quality of life (QOL). The results obtained in this study contribute to a better understanding of the clinical and demographic characteristics of patients with rheumatic diseases at the beginning of anti-TNF-agent treatment by SUS. Furthermore, our findings are consistent with another Brazilian and foreign cross-sectional investigations. This knowledge can be of great importance for further studies evaluating the effectiveness of biological agents, as well as, to contribute to improve the well-being of the patients with rheumatic diseases.info:eu-repo/semantics/openAccessUniversidade de São Paulo, Faculdade de Ciências FarmacêuticasBrazilian Journal of Pharmaceutical Sciences v.51 n.3 20152015-09-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502015000300709en10.1590/S1984-82502015000300023 |
institution |
SCIELO |
collection |
OJS |
country |
Brasil |
countrycode |
BR |
component |
Revista |
access |
En linea |
databasecode |
rev-scielo-br |
tag |
revista |
region |
America del Sur |
libraryname |
SciELO |
language |
English |
format |
Digital |
author |
Oliveira Junior,Haliton Alves de Almeida,Alessandra Maciel Acurcio,Francisco Assis Santos,Jéssica Barreto dos Kakehasi,Adriana Maria Alvares,Juliana Dabés,Clarice Gomes e Souza Cherchiglia,Mariangela Leal |
spellingShingle |
Oliveira Junior,Haliton Alves de Almeida,Alessandra Maciel Acurcio,Francisco Assis Santos,Jéssica Barreto dos Kakehasi,Adriana Maria Alvares,Juliana Dabés,Clarice Gomes e Souza Cherchiglia,Mariangela Leal Profile of patients with rheumatic diseases undergoing treatment with anti-TNF agents in the Brazilian Public Health System (SUS), Belo Horizonte - MG |
author_facet |
Oliveira Junior,Haliton Alves de Almeida,Alessandra Maciel Acurcio,Francisco Assis Santos,Jéssica Barreto dos Kakehasi,Adriana Maria Alvares,Juliana Dabés,Clarice Gomes e Souza Cherchiglia,Mariangela Leal |
author_sort |
Oliveira Junior,Haliton Alves de |
title |
Profile of patients with rheumatic diseases undergoing treatment with anti-TNF agents in the Brazilian Public Health System (SUS), Belo Horizonte - MG |
title_short |
Profile of patients with rheumatic diseases undergoing treatment with anti-TNF agents in the Brazilian Public Health System (SUS), Belo Horizonte - MG |
title_full |
Profile of patients with rheumatic diseases undergoing treatment with anti-TNF agents in the Brazilian Public Health System (SUS), Belo Horizonte - MG |
title_fullStr |
Profile of patients with rheumatic diseases undergoing treatment with anti-TNF agents in the Brazilian Public Health System (SUS), Belo Horizonte - MG |
title_full_unstemmed |
Profile of patients with rheumatic diseases undergoing treatment with anti-TNF agents in the Brazilian Public Health System (SUS), Belo Horizonte - MG |
title_sort |
profile of patients with rheumatic diseases undergoing treatment with anti-tnf agents in the brazilian public health system (sus), belo horizonte - mg |
description |
The aim of this study was to describe the baseline demographic and clinical characteristics as well as the functional status of a prospective cohort of patients with rheumatic diseases assisted by the Brazilian Public Health System (SUS). Data for 302 patients receiving tumor necrosis factor α inhibitors (anti-TNF agents) was collected through a standard form. Among patients, 229 (75.8%) were female and 155 (51.3%) were Caucasian; the mean age was 50.3 ± 12.8 years, and the mean disease duration was 9.9 ± 8.7 years. Among them 214 patients (70.9%) received adalimumab, 72 (23.8%) etanercept, and 16 (5.3%) infliximab. Mean Health Assessment Questionnaire-Disability Index (HAQ-DI) was 1.37 ± 0.67 for all participants. Poor functional response was associated with female gender, married patients and with a score of < 0.6 on the EuroQoL-5 dimensions (EQ-5D). Significant correlation was found between the HAQ-DI values, disease activity and quality of life (QOL). The results obtained in this study contribute to a better understanding of the clinical and demographic characteristics of patients with rheumatic diseases at the beginning of anti-TNF-agent treatment by SUS. Furthermore, our findings are consistent with another Brazilian and foreign cross-sectional investigations. This knowledge can be of great importance for further studies evaluating the effectiveness of biological agents, as well as, to contribute to improve the well-being of the patients with rheumatic diseases. |
publisher |
Universidade de São Paulo, Faculdade de Ciências Farmacêuticas |
publishDate |
2015 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502015000300709 |
work_keys_str_mv |
AT oliveirajuniorhalitonalvesde profileofpatientswithrheumaticdiseasesundergoingtreatmentwithantitnfagentsinthebrazilianpublichealthsystemsusbelohorizontemg AT almeidaalessandramaciel profileofpatientswithrheumaticdiseasesundergoingtreatmentwithantitnfagentsinthebrazilianpublichealthsystemsusbelohorizontemg AT acurciofranciscoassis profileofpatientswithrheumaticdiseasesundergoingtreatmentwithantitnfagentsinthebrazilianpublichealthsystemsusbelohorizontemg AT santosjessicabarretodos profileofpatientswithrheumaticdiseasesundergoingtreatmentwithantitnfagentsinthebrazilianpublichealthsystemsusbelohorizontemg AT kakehasiadrianamaria profileofpatientswithrheumaticdiseasesundergoingtreatmentwithantitnfagentsinthebrazilianpublichealthsystemsusbelohorizontemg AT alvaresjuliana profileofpatientswithrheumaticdiseasesundergoingtreatmentwithantitnfagentsinthebrazilianpublichealthsystemsusbelohorizontemg AT dabesclaricegomesesouza profileofpatientswithrheumaticdiseasesundergoingtreatmentwithantitnfagentsinthebrazilianpublichealthsystemsusbelohorizontemg AT cherchigliamariangelaleal profileofpatientswithrheumaticdiseasesundergoingtreatmentwithantitnfagentsinthebrazilianpublichealthsystemsusbelohorizontemg |
_version_ |
1756437794813640704 |